Rapport Therapeutics, Inc. Financing Cash Flow
Rapport Therapeutics, Inc. (RAPP) reported Financing Cash Flow of $1.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- Rapport Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.41M.
- Rapport Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $531.00K, a 10520.00% increase year-over-year.
- Rapport Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $311.00K, a 4342.86% increase year-over-year.
- Rapport Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $270.53M.
- Rapport Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $270.79M, a 22.18% increase from fiscal 2024.
- Rapport Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $221.63M, a 52.70% increase from fiscal 2023.
- Rapport Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $145.14M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.94M 10-Q · filed 2026-08-05 | $2.25M derived: sum of 3 quarters · filed 2026-08-05 | $272.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $531.00K 10-Q · filed 2026-05-07 | $842.00K derived: sum of 2 quarters · filed 2026-05-07 | $271.38M derived: sum of 3 quarters · filed 2026-05-07 | $271.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $311.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $270.84M derived: sum of 2 quarters · filed 2026-03-10 | $270.78M derived: sum of 3 quarters · filed 2026-08-05 | $270.79M 10-K · filed 2026-03-10 |
| 2025-09-30 | $270.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $270.47M derived: sum of 2 quarters · filed 2026-08-05 | $270.48M 10-Q · filed 2025-11-06 | $270.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$58.00K 10-Q · filed 2026-08-05 | -$51.00K derived: sum of 3 quarters · filed 2026-08-05 | -$1.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $5.00K 10-Q · filed 2026-05-07 | $12.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.38M derived: sum of 3 quarters · filed 2026-05-07 | $157.97M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$1.39M derived: sum of 2 quarters · filed 2026-03-10 | $157.97M derived: sum of 3 quarters · filed 2026-03-10 | $221.63M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $157.96M derived: sum of 2 quarters · filed 2025-11-06 | $221.62M 10-Q · filed 2025-11-06 | $221.48M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $159.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $223.01M 10-Q · filed 2025-08-07 | $222.87M derived: sum of 3 quarters · filed 2025-08-07 | $308.23M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $63.66M 10-Q · filed 2025-05-08 | $63.52M derived: sum of 2 quarters · filed 2025-05-08 | $148.88M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $85.22M derived: sum of 2 quarters · filed 2025-03-11 | $145.14M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $85.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $145.28M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $59.92M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |